Transition Agreements in the Biotechnology Industry
129 Contracts & Agreements
- 2seventy bio, Inc. (2 contracts)
- AbbVie Inc. (2)
- ACADIA PHARMACEUTICALS INC (2)
- ADMA BIOLOGICS, INC. (2)
- Alector, Inc. (1)
- Alkermes plc. (2)
- Allena Pharmaceuticals, Inc. (2)
- Alliqua BioMedical, Inc. (2)
- Allogene Therapeutics, Inc. (1)
- Allovir, Inc. (1)
- Altimmune, Inc. (1)
- Aptevo Therapeutics Inc. (3)
- Arcellx, Inc. (1)
- Arcutis Biotherapeutics, Inc. (1)
- Athenex, Inc. (1)
- Aura Biosciences, Inc. (2)
- AVROBIO, Inc. (1)
- BioAtla, Inc. (1)
- Biogen Inc. (1)
- BIOMARIN PHARMACEUTICAL INC (4)
- Biostage, Inc. (2)
- BIOTIME INC (2)
- bluebird bio, Inc. (3)
- CANCER GENETICS, INC (1)
- CATALYST BIOSCIENCES, INC. (2)
- CATALYST PHARMACEUTICALS, INC. (2)
- Celsion CORP (1)
- Constellation Alpha Capital Corp. (1)
- CONTRAFECT Corp (1)
- Cyclerion Therapeutics, Inc. (2)
- CytoDyn Inc. (1)
- CytomX Therapeutics, Inc. (1)
- Deciphera Pharmaceuticals, Inc. (2)
- Dermira, Inc. (1)
- Dicerna Pharmaceuticals Inc (2)
- Esperion Therapeutics, Inc. (1)
- EXACT SCIENCES CORP (1)
- FIBROGEN INC (2)
- Gain Therapeutics, Inc. (1)
- GERON CORP (2)
- Gilead Sciences (0)
- GLYCOMIMETICS INC (1)
- Gossamer Bio, Inc. (1)
- Grail, Inc. (1)
- GTX INC (1)
- iBio, Inc. (1)
- IMMUNOMEDICS INC (1)
- Karyopharm Therapeutics Inc. (4)
- Mirum Pharmaceuticals, Inc. (1)
- Moderna, Inc. (1)
- NEWLINK GENETICS CORP (1)
- NTN BUZZTIME INC (1)
- Nuo Therapeutics, Inc. (2)
- OncoCyte Corp (1)
- OPGEN INC (1)
- Passage BIO, Inc. (0)
- PDL BIOPHARMA, INC. (2)
- Pfenex Inc. (2)
- Praxis Precision Medicines, Inc. (1)
- Progenics Pharmaceuticals, Inc. (2)
- PUMA BIOTECHNOLOGY, INC. (1)
- Radius Health, Inc. (2)
- RECURSION PHARMACEUTICALS, INC. (1)
- Retrophin, Inc. (1)
- RIGEL PHARMACEUTICALS INC (1)
- Sana Biotechnology, Inc. (1)
- SELECTA BIOSCIENCES INC (3)
- Seres Therapeutics, Inc. (1)
- Sierra Oncology, Inc. (1)
- SOLENO THERAPEUTICS INC (1)
- Spring Bank Pharmaceuticals, Inc. (1)
- SQZ Biotechnologies Co (4)
- SUNESIS PHARMACEUTICALS INC (2)
- Surface Oncology, Inc. (1)
- Talaris Therapeutics, Inc. (1)
- Tonix Pharmaceuticals Holding Corp. (1)
- Tyra Biosciences, Inc. (0)
- Ultragenyx Pharmaceutical Inc. (3)
- Vaxart, Inc. (1)
- Vericel Corp (5)
- VICAL INC (2)
- Viela Bio, Inc. (1)
- Vigil Neuroscience, Inc. (1)
- VITAL THERAPIES INC (1)
- XBiotech Inc. (2)
- Xenetic Biosciences, Inc. (1)
- Executive Transition Agreement, dated September 23, 2024, by and between the Company and Stephen R. Davis (ACADIA PHARMACEUTICALS INC, Filed With SEC on September 23, 2024)
- Transition Agreement, dated as of August 29, 2024, between the Company and Michael Mason (Karyopharm Therapeutics Inc., Filed With SEC on August 29, 2024)
- Form of Transition Services Agreement, by and between Seres Therapeutics, Inc. and Socit des Produits Nestl S.A (Seres Therapeutics, Inc., Filed With SEC on August 6, 2024)
- Transition Agreement, dated August 3, 2024, by and between Esperion Therapeutics, Inc. and JoAnne Foody (Esperion Therapeutics, Inc., Filed With SEC on August 5, 2024)
- Transition Agreement between the Registrant and Shafique Virani (RECURSION PHARMACEUTICALS, INC., Filed With SEC on May 9, 2024)
- Termination and Transition Agreement to Development and Commercialization Agreement (for the U.S. and Certain Other Territories), by and between AstraZeneca AB and FibroGen, Inc.,... (FIBROGEN INC, Filed With SEC on May 6, 2024)
- Employee Relocation and Transition Benefits Agreement, by and between AVROBIO, Inc. and Azadeh Golipour, dated January 31, 2022 (AVROBIO, Inc., Filed With SEC on February 14, 2024)
- Transition Services Agreement, dated as of November 13, 2023, by and between Mural Oncology, Inc. and Alkermes, Inc (Alkermes plc., Filed With SEC on November 15, 2023)
- Transition Services Agreement, dated as of November 13, 2023, by and between Alkermes, Inc. and Mural Oncology, Inc (Alkermes plc., Filed With SEC on November 15, 2023)
- Transition and Release Agreement, dated November 6, 2023, by and between Cadmus Rich and the Registrant (Aura Biosciences, Inc., Filed With SEC on November 9, 2023)
- Transition and Release Agreement, dated September 28, 2023, by and between Cadmus Rich and the Registrant (Aura Biosciences, Inc., Filed With SEC on November 9, 2023)
- Transition Agreement between the Registrant and Marshelle Smith Warren, dated October 3, 2023 (SQZ Biotechnologies Co, Filed With SEC on November 8, 2023)
- Transition Agreement between the Registrant and Lawrence Knopf, dated October 3, 2023 (SQZ Biotechnologies Co, Filed With SEC on November 8, 2023)
- Transition Agreement between the Registrant and Richard Capasso, dated October 3, 2023 (SQZ Biotechnologies Co, Filed With SEC on November 8, 2023)
- Transition Agreement between the Registrant and Howard Bernstein, dated October 3, 2023 (SQZ Biotechnologies Co, Filed With SEC on November 8, 2023)
- Transition Agreement effective as of August 22, 2023 by and between CytomX Therapeutics, Inc., and AbbVie Global Enterprises Ltd (CytomX Therapeutics, Inc., Filed With SEC on November 7, 2023)
- Transition Agreement b (Deciphera Pharmaceuticals, Inc., Filed With SEC on October 30, 2023)
- Amendment to Transition Services Agreement between Eisai Inc., a subsidiary of Eisai and the Company, dated as of July 31, 2023 (certain identified information has been excluded... (CATALYST PHARMACEUTICALS, INC., Filed With SEC on August 9, 2023)
- Amendments 1, 2 and 3 to License and Transition Services Agreement with Forma Therapeutics, Inc (RIGEL PHARMACEUTICALS INC, Filed With SEC on August 1, 2023)
- TRANSITION SERVICES AGREEMENT (Tonix Pharmaceuticals Holding Corp., Filed With SEC on July 3, 2023)
- Transition Agreement and Release by and between the Company and Sunil Agarwal, dated as of April 28, 2023 (Sana Biotechnology, Inc., Filed With SEC on May 8, 2023)
- Transition Agreement, by and between the Company and John Dobak, dated March 1, 2023 (Constellation Alpha Capital Corp., Filed With SEC on May 4, 2023)
- Transition Agreement dated February 21, 2023, by and between the Company and John Magnani, Ph.D (GLYCOMIMETICS INC, Filed With SEC on May 3, 2023)
- Transition and Release Agreement, by and between Fresh Tracks Therapeutics, Inc. and Robert B. Brown, dated as of February 1, 2023 (VICAL INC, Filed With SEC on February 7, 2023)
- Form of Transition Services Agreement between Eisai, Inc., a subsidiary of Eisai, and the Company (certain identified information has been excluded from the exhibit because it... (CATALYST PHARMACEUTICALS, INC., Filed With SEC on December 22, 2022)
- Transition Agreement, by and between the Registrant and Suzanne T. Ildstad, dated August 13, 2022 (Talaris Therapeutics, Inc., Filed With SEC on November 10, 2022)
- Transition Agreement, by and between the Company and Eric Richman, dated September 19, 2022 (Gain Therapeutics, Inc., Filed With SEC on September 20, 2022)
- Transition Agreement and Release, dated as of August 14, 2022, by and between Cara Cassino, M.D. and ContraFect Corporation (CONTRAFECT Corp, Filed With SEC on August 16, 2022)
- Amendment to the Transition Services Agreement, by and between 2seventy bio, Inc. and the Registrant (bluebird bio, Inc., Filed With SEC on August 4, 2022)
- Transition Agreement dated July 26, 2022, by and between Praxis Precision Medicines, Inc. and Bernard Ravina (Praxis Precision Medicines, Inc., Filed With SEC on July 26, 2022)
- Transition Services Agreement, dated as of (VICAL INC, Filed With SEC on May 3, 2022)
- Transition Agreement, dated March 28, 2022, between the Company and Sharon Shacham (Karyopharm Therapeutics Inc., Filed With SEC on March 29, 2022)
- Transition Agreement, dated March 28, 2022, between the Company and Michael G. Kauffman (Karyopharm Therapeutics Inc., Filed With SEC on March 29, 2022)
- Transition Agreement and Release dated March 22, 2022 between the Company and Mark Kowalski (Sierra Oncology, Inc., Filed With SEC on March 23, 2022)
- Transition Agreement and Release between the Registrant and David Hilbert, Ph.D., dated January 7, 2022 (Arcellx, Inc., Filed With SEC on January 14, 2022)
- Transition Agreement, by and between the Registrant and Richard A. Fisher, dated November 17, 2021 (Vigil Neuroscience, Inc., Filed With SEC on November 19, 2021)
- Amendment to Executive Transition Services Agreement (Aptevo Therapeutics Inc., Filed With SEC on November 12, 2021)
- Executive Transition Services Agreement (Aptevo Therapeutics Inc., Filed With SEC on November 12, 2021)
- Transition Agreement by and between FibroGen, Inc. and Pat Cotroneo, dated as of August 14, 2021 (FIBROGEN INC, Filed With SEC on November 9, 2021)
- Transition Services Agreement, dated as of November 3, 2021, by and between 2seventy bio, Inc. and bluebird bio, Inc (2seventy bio, Inc., Filed With SEC on November 4, 2021)
